K163026 is an FDA 510(k) clearance for the Ultra/Phonic Scanning Gel. Classified as Media, Coupling, Ultrasound (product code MUI), Class II - Special Controls.
Submitted by Pharmaceutical Innovations, Inc. (Newark, US). The FDA issued a Cleared decision on January 9, 2018 after a review of 435 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.1570 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Radiology submissions.
View all Pharmaceutical Innovations, Inc. devices